

United States Parent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/713,780	11/15/2000	Fatih M. Uckun	12152.109US01	3061
23552	7590 12/12/2001			
MERCHANT & GOULD PC			EXAMINER	
P.O. BOX 2903 MINNEAPOLIS, MN 55402-0903			PAK, JOHN D	
			ART UNIT	PAPER NUMBER
			1616	
			DATE MAILED: 12/12/2001	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No
Application No

Applicano

09/713,780

Examiner

Office Action Summary

Art Unit 1616

UCKUN



Pak, J. -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE ONE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 1) Responsive to communication(s) filed on _____ 2b) X This action is non-final. 2a) This action is FINAL. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims is/are pending in the application. 4) X Claim(s) 1-24 4a) Of the above, claim(s) ______ is/are withdrawn from consideration. 5) Claim(s) ______ is/are allowed. 6) Claim(s) ______ is/are rejected. 7) Claim(s) ______ is/are objected to. 8) X Claims 1-24 are subject to restriction and/or election requirement. **Application Papers** 9) \square The specification is objected to by the Examiner. 10) The drawing(s) filed on ______ is/are objected to by the Examiner. 11) The proposed drawing correction filed on ______ is: a) approved b) disapproved. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) All b) Some* c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. _ 3.
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 18) Interview Summary (PTO-413) Paper No(s). 15) Notice of References Cited (PTO-892) 19) Notice of Informal Patent Application (PTO-152) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 20) Other: 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).

Serial Number: 09/713,780

Art Unit: 1616

Claims 1-24 are pending in this application.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-16, drawn to method for inhibiting angiogenesis.
- II. Claims 17, 19-24, drawn to method for treating or preventing diabetic retinopathy.
- III. Claim 18, drawn to method for treating restenosis following coronary angioplasty.

Applicant is *further required* to elect for examination purposes a single disclosed species of vanadium compound, i.e. a single specific compound wherein the structural formula and all R substituents are defined.

The three inventions as set forth above are distinct, each from the others, because they are each directed to divergent therapeutic treatment methods, which three divergent methods are evidence themselves of distinctness. A search and review of prior art documents for one method invention would not be a complete search and review of prior art documents for the other therapeutic method inventions. Under the present fact situation, taken in view of the complexity of technology involved here and the breadth of vanadium compounds encompassed, a search and examination of more than one invention group would place an undue burden on the Examiner if the restriction were not required.

Therefore, for reasons of distinctness and undue burden, the restriction requirement is deemed proper.

Serial Number: 09/713,780

Art Unit: 1616

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

A facsimile center has been established in Technology Center 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machines are (703) 308-4556 or (703) 305-3592.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Examiner Pak whose telephone number is (703) 308-4538. The Examiner can normally be reached on Monday through Thursday from 8:00 AM to 5:30 PM. The Examiner can also be reached on alternate Fridays.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Mr. José Dees, can be reached on (703) 308-4628.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

JOHN PAK PRIMARY EXAMINER GROUP 1000